Immunotherapeutic Strategies for the Treatment of Glioma

Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.
The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.
This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma.

Autorentext
Dr. Jackson is a senior resident in Neurosurgery at Johns Hopkins. He obtained his MD from the Johns Hopkins University School of Medicine. He completed his chief residency in June 2018 and is currently working as a postdoctoral fellow in neuro-oncology. His research interests focus on interactions between brain tumors and the host immune system, particularly local, regional, and systemic mechanisms of immune suppression Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

Klappentext
Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.
The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.
This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma.

Inhalt

1. Peptide vaccines 2. Dendritic cell vaccines 3. Heat shock protein vaccines 4. Immune checkpoint blockade 5. Targeting myeloid cells in glioblastoma 6. Oncolytic viruses 7. CAR T cell therapy 8. Mechanisms of immune suppression in glioblastoma patients 9. Immunogenomics in glioblastoma